You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK):旗下新藥Birociclib向美國ASCO投稿獲接受
阿思達克 04-14 12:38
四環醫藥(00460.HK)宣布,旗下軒竹生物根據在研1類新藥(口比)羅西尼(Birociclib)II期研究結果,於2023年2月10日向2023年美國臨床腫瘤學會(ASCO)投稿。 集團表示,目前已接到通知,投稿將於2023年6月4日在海報論文(PosterSession)展示。 臨床I期研究結果表明,作為一個全新結構的CDK4/6抑制劑,Birociclib有望克服激素受體陽性(HR+)乳腺癌患者內分泌治療的耐藥問題;同時亦觀察到Birociclib單藥針對多線治療失敗的晚期乳腺癌患者有明顯療效。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account